Quectel Strengthens GNSS Offering with RTKHOLD and Galileo OSNMA and High Accuracy Service Integration
7.10.2025 09:00:00 CEST | Business Wire | Press Release
Quectel Wireless Systems, an end-to-end global IoT solutions provider, today announces the addition of two new technologies to its LG290P, LG580P and LG680P high precision modules, RTKHOLD and Galileo Open Service Navigation Message Authentication (OSNMA) and High Accuracy Service (HAS). Designed to increase the accuracy of GNSS positioning anywhere globally, RTKHOLD, a technology developed by Quectel, allows receivers to intelligently extend the usability of previously received corrections for up to ten minutes. OSNMA is Galileo’s new signal authentication service while the HAS delivers decimeter-level positioning anywhere in the world, directly via satellite or cellular connectivity.
Real-Time Kinematic (RTK) technology is a leading method for achieving centimeter-level accuracy in GNSS applications. By using correction data from a base station or correction service, RTK can refine positioning accuracy from the meter range down to just a few centimeters. This correction data, typically transmitted in RTCM3 format, reaches the rover receiver via cellular, radio, satellite, or other channels, but stable connectivity is critical to sustain this precision.
When correction signals are interrupted, accuracy degrades quickly. Within just 15–30 seconds without updates, positioning can drift by 2–5 cm and longer gaps typically force a fallback to sub-meter or even meter-level precision. This issue is especially problematic in rural environments, precision agriculture, and applications reliant on short-range links like radio or LoRa, where dropouts are frequent. For many automation tasks, such a loss of accuracy is unacceptable.
With Quectel’s RTKHOLD technology, the receiver can model how GNSS errors evolve over time, enabling it to predict corrections and maintain centimeter-level accuracy even when the live correction stream is temporarily unavailable. This significantly improves the robustness of RTK in real-world deployments, ensuring that temporary link losses no longer render high-precision applications unusable. RTKHOLD is already supported in the LG290P A06 firmware. Support for the LG580P and LG680P will be available soon.
In addition, Galileo HAS, a free service provided by the EU’s Galileo satellite navigation system that delivers precise positioning corrections to improve accuracy beyond standard GPS/GNSS levels, will be coming to the LG290P, LG580P and LG680P in Q4 2025. With a number of industries, including agriculture and rail, relying on precise positioning to enable smarter, safer and more efficient operations, HAS enables precision without any connectivity restraints as it enables high precision positioning wherever Galileo satellites are visible.
Finally, Quectel has also added support for Galileo OSNMA to its LC29H GNSS module, bringing cryptographic signal authentication to IoT applications. OSNMA, which became a formal service on 24 July 2025, uses digital signatures to verify that navigation messages truly originate from Galileo satellites, protecting against spoofing attacks that can falsify position and time data. By upgrading to the latest firmware, Quectel customers can immediately integrate authenticated GNSS into devices such as smart tachographs, fleet telematics systems, autonomous vehicles, and critical infrastructure solutions—ensuring compliance, security, and trusted positioning without hardware changes.
“Quectel is committed to advancing positioning performance through continuous innovation,” said Windy Fang, Director, GNSS Product Line, Quectel Wireless Solutions. “By introducing RTKHOLD alongside Galileo’s OSNMA and HAS capabilities, we’re strengthening the reliability, accuracy, and security of our high-precision modules, ensuring our customers can deliver smarter, safer and more resilient IoT solutions anywhere in the world.”
Quectel will be present at Intergeo 2025 in Frankfurt where the team will be available to talk about the additional functionality of Quectel’s GNSS modules and can found on booth 0E103 in Hall 12.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are an end-to-end global IoT solutions provider backed by outstanding support and services.
With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com or LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007212262/en/
Contacts
Media contact: media@quectel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom